Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report) insider Abraham Chesed acquired 14,286 shares of the stock in a transaction that occurred on Thursday, October 23rd. The shares were bought at an average price of $4.60 per share, for a total transaction of $65,715.60. Following the transaction, the insider owned 1,447,268 shares of the company’s stock, valued at $6,657,432.80. This trade represents a 1.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Turn Therapeutics Stock Performance
Turn Therapeutics Company Profile
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.
Recommended Stories
- Five stocks we like better than Turn Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- These 3 High-Momentum ETFs Are Riding the Tech Wave
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Verizon Results Trigger Rebound in High-Yield Stock
- The Role Economic Reports Play in a Successful Investment Strategy
- Picks & Shovels: Investing in the Physical Foundation of AI
Receive News & Ratings for Turn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
